TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03437291

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion

Intervention type: PROCEDURE
Intervention: Cesarean section
Description: Lower segment CS with evaluation of Placental site, spontaneous separation, placental invasion into the bladder and other surrounding organs, Uterotonic administration, Bladder , ureteric or bowel injury, blood loss and blood transfusion

Intervention type: DEVICE
Intervention: Transabdominal ultrasound
Description: loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass

Intervention type: DEVICE
Intervention: Transabdominal ultrasound
Description: loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass

Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass

Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: loss of clear zone, Abnormal placental lacunae, Bladder wall interruption, Myometrial thinning, Placental bulge, Focal exophytic mass
Study: NCT01001572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan/amlodipine 160/5 mg
Description: Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan 160 mg
Description: Valsartan 160 mg capsule taken orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 160 mg
Description: Valsartan 160 mg capsule taken orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 1 capsule or tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 capsule or tablet taken orally once daily
Study: NCT03375723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information on anatomy and physiology, and breathing technique
Description: The patients in the treatment group receive information about what acute PE is regarding anatomy and physiology, a review of what causes the respiratory associated pain in acute PE and also a review of the breathing technique to manage their respiratory associated pain. The given information is standardized and the patient also receives written information with both text and pictures. Patients in the treatment group will meet the physiotherapist at day 1, 2 and the patients also has an opportunity to see the physiotherapist or talk to her at the phone if there are any questions concerning the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care treatment
Description: Usual care treatment given to patients with respiratory associated pain in acute PE, which is treatment with analgesics. The information on anatomy and physiology in acute PE is the usual information given by the physician at the ward that the patient is treated.
Study: NCT04373018

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hypochlorite
Description: Sodium hypochlorite irrigant will be used during biomechanical preparation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Chlorhexidine irrigant will be used during biomechanical preparation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine + Hydrogen peroxide
Description: Chlorhexidine + Hydrogen peroxide irrigant will be used during biomechanical preparation.
Study: NCT01958554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Study: NCT01186367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Linear Aerobic Training
Description: The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nonlinear Aerobic Training
Description: The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Stretching
Description: All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise test (CPET)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Complete blood count

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Complete blood count

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Complete blood count
Study: NCT02701179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 1% concentration solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine 2% concentration solution
Study: NCT01706731

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
Study: NCT02065349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASP8477
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT04303429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX/XELOX/Capecitabine
Description: Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
Study: NCT02752490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liberal use of maternal oxygen
Description: Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indicated use of maternal oxygen
Description: Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
Study: NCT02130674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dipeptiven
Description: two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
Study: NCT01941927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2141795
Description: GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki\*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Since phosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA. GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
Study: NCT04501939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab
Description: Cycle 1, Day 1 \& 15 - 600mg Cycle 2, Day 1 to Cycle 6, Day 1 - 600mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400mg PO daily from cycle 1 day 1 for 6 cycles of 28 days.
Study: NCT04304053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment and prophylaxis
Description: Cases will be offered a therapeutic regimen hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7~Contacts will be offered a prophylactic regimen of hydroxychloroquine (200mg tablets) 800mg on day 1, and 400mg on days 2-7.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Public Health measures
Description: Isolation of patient and contact tracing as per national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Public Health measures
Description: Isolation of patient and contact tracing as per national guidelines.
Study: NCT00848237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation (HALO Ablation Systems)
Description: Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
Study: NCT00981162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative study
Study: NCT02981862

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CaptHPV method
Description: 20 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.~In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology~The results of both analyzes will be compared blindly.
Study: NCT04062981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carisbamate
Description: An oral liquid formulation (20 mg/mL) of carisbamate (S-carisbamate)
Study: NCT02454530

Intervention type: BIOLOGICAL
Intervention: Nivestim®
Study: NCT05113420

Intervention type: DRUG
Intervention: Detralex
Description: Diosmin+ Hesperidin

Intervention type: DRUG
Intervention: Detralex
Description: Diosmin+ Hesperidin

Intervention type: DRUG
Intervention: Detralex
Description: Diosmin+ Hesperidin

Intervention type: DRUG
Intervention: Detralex
Description: Diosmin+ Hesperidin

Intervention type: DRUG
Intervention: Troxevasin
Description: Troxerutin

Intervention type: DRUG
Intervention: Troxevasin
Description: Troxerutin
Study: NCT01094808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: FDA approved medication (capsules) at 75 mg and 200 mg doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: FDA approved medication (capsules) at 75 mg and 200 mg doses
Study: NCT01603498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 40mg
Study: NCT00681213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral/Sirolimus
Study: NCT00804648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate in Sorbate
Description: 0.5%
Study: NCT04353518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suspension of heat killed (autoclaved) Mycobacterium w
Description: Subjects randomized to Test arm will receive intraderma Mw in divided doses at least 2 cm away from first injection site in the deltoid region.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo arm will receive intraderma Placebo in divided doses at least 2 cm away from first injection site in the deltoid region.
Study: NCT04057612

Intervention type: OTHER
Intervention: Esophagus temperature monitoring
Description: Measuring core temperature by esophageal stethoscope

Intervention type: OTHER
Intervention: Carotid artery temperature monitoring
Description: Measuring temperature on skin near to carotid artery using 3M™ Bair Hugger™ temperature monitoring system
Study: NCT01429415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate Sandoz
Description: Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride , USP PPC
Description: Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
Study: NCT00691860

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh (Ultrapro ®)
Description: In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional sigmoid end colostomy
Description: Patients receiving conventional sigmoid end colostomy, without mesh

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional sigmoid end colostomy
Description: Patients receiving conventional sigmoid end colostomy, without mesh
Study: NCT04108793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy exercises
Description: The intervention group will receive an extended home-based rehabilitation program twice a week continued for 3 months (12 weeks) after discharge funded by the study.
Study: NCT01094808

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bowel preparation
Description: Polyethylene glycol electrolyte solution bowel preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Description: Polyethylene glycol electrolyte solution bowel preparation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Description: Polyethylene glycol electrolyte solution bowel preparation
Study: NCT01774292

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation with injection of liquid in the cuff

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endotracheal intubation with injection of liquid in the cuff
Study: NCT02546310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0009936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0009936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HTL0009936 matching placebo
Study: NCT04062370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6. Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser photocoagulation
Description: After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser photocoagulation
Description: After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
Study: NCT01559701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00345439
Description: 5-80 mg twice-a-day for 12 months
Study: NCT04220138

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anterior chamber illumination in cataract surgery
Description: This will be a prospective interventional case series, patients with cataract and poor red reflex will undergo phacoemulsification assisted by anterior chamber illumination to overcome the problem of poor red reflex.
Study: NCT01939093

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B1-6-12
Description: All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B1-6-12
Description: All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stugeron
Description: All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stugeron
Description: All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
Study: NCT01242254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of KH902
Description: 0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of KH902
Description: 0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
Study: NCT00150345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole (Vfend)
Description: voriconazole, early treatment

Intervention type: DRUG
Group type: OTHER
Intervention: voriconazole (Vfend)
Description: voriconazole, deferred treatment
Study: NCT04399980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavrilimumab
Description: Treatment infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo infusion
Study: NCT02967484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: 1. Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).~2. Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).~3. Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.~The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)
Study: NCT01138696

Intervention type: OTHER
Intervention: Questionnaires
Description: KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),

Intervention type: OTHER
Intervention: Questionnaires
Description: KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),

Intervention type: OTHER
Intervention: RX
Description: X-rays and clinical investigation of the knee 20 years after surgery

Intervention type: OTHER
Intervention: RX
Description: X-rays and clinical investigation of the knee 20 years after surgery
Study: NCT02713113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex reversal of neuromuscular blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex reversal of neuromuscular blockade

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex reversal of neuromuscular blockade
Study: NCT02254044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivatuzumab mertansine